BRONCHENOL COUGH ® Dextromethorphan

BRONCHENOL COUGH ® is a drug based on dextromethorphan hydrobromide

THERAPEUTIC GROUP: Cough suppressants

Indications COUGH BRONCHENOL ® Dextromethorphan

BRONCHENOL COUGH ® is used in the symptomatic treatment of cough.

Mechanism of action BRONCHENOL COUGH ® Dextromethorphan

BRONCHENOLO TOSSE ® is a drug based on dextromethorphan, a synthetic derivative of morphine, however, without the typical opiate activity.
Taken orally, Dextromethorphan is rapidly and effectively absorbed by the mucosa of the gastrointestinal tract, and following a first pass metabolism, distributed among the various tissues, where it carries out its biological activity.
More precisely at the central nervous level, this active principle, interacting with non-opioid receptors, increases the concentrations of Serotonin, thus carrying out a modest sedative action, mainly concentrated at the level of the cough center.
The cough-depressing activity, effective both in the course of cold syndromes and in the course of allergic diseases, lasts several hours, at the end of which, after a further hepatic metabolism, Dextromethorphan, in the form of different catabolites, is eliminated through the urine.

Studies carried out and clinical efficacy

Arch Med Sadowej Kryminol. 2012 Jul-Sep; 62: 197-202.

[Dextromethorphan (DXM): new methods of intoxications among teenagers - a case description].

Tomczak E, Wiergowski M, Jankowski Z, Wilmanowska JA.

Case report that denounces the ever increasing number of cases in the youth population of intoxications associated with the abuse of over-the-counter drugs containing centrally acting substances, with euphoric or sedating power such as dextromethorphan.

Indian J Pediatr. 2013 Apr 17.

To Compare the Effect of Dextromethorphan, Promethazine and Placebo on Nocturnal Cough in Children Aged 1-12 y with Upper Respiratory Infections: A Randomized Controlled Trial.

Bhattacharya M, Joshi N, Yadav S.

Work that demonstrates the inability of dextromethorphan to quell nocturnal cough in small patients aged between 1 and 12 years with infectious diseases of the upper respiratory tract.
Probably this failure is determined by the spontaneous resolution of cough at night in this type of pathology

Pediatr Neurol. 2013 Mar; 48: 200-5. doi: 10.1016 / j.pediatrneurol.2012.11.003.

Efficacy of dextromethorphan and cyclosporine a for acute encephalopathy.

Matsuo M, Maeda T, Ono N, Sugihara S, Kobayashi I, Koga D, Hamasaki Y.

Interesting study that demonstrates how the combined treatment between Dextromethorphan and Cyclosporine A can be effective in the treatment and prevention of encephalopathy, reducing the incidence of serious clinical complications.

Method of use and dosage

154 mg dextromethorphan hydrobromide syrup per 100 ml of syrup.
7.5 mg tablets of Dextromethorphan hydrobromide.
Effective therapeutic dosages in adults generally fall within the daily 60 mg of Dextromethorphan hydrobromide divided into 3-4 intakes.
Halved dosages, on the other hand, are used in children, for whom, however, medical supervision would be advisable in any case.
Therapy should not extend beyond 5-7 days of treatment without consulting your doctor.

Warnings COUGH BRONCHENOL ® Dextromethorphan

In order to ensure a good therapeutic result and minimize potential side effects, it would be advisable for the patient to consult a doctor before taking BRONCHENOL COUGH ®.
In fact, the use of this drug should take place with particular caution in patients suffering from chronic or persistent respiratory diseases, liver diseases and renal diseases, for which the variation of the pharmacokinetic characteristics of Dextromethorphan could determine the onset of potential side effects.
BRONCHENOLO TOSSE ® contains sucrose, therefore its use is contraindicated in patients with sucrase enzyme deficiency, fructose intolerance and glucose-galactose malabsorption.
It is recommended to store the drug out of the reach of children.
BRONCHENOL COUGH ® may cause drowsiness, making it dangerous to drive or use machines.


Given the absence of studies capable of characterizing the safety profile of dextromethorphan for the health of the unborn child, it would be advisable to avoid the use of this drug during pregnancy and in the subsequent period of breastfeeding.


In order to avoid the incidence of potential side effects, it would be advisable that patients receiving antidepressants, monoamine oxidase inhibitors, serotonin reuptake inhibitors, tricyclic antidepressants, inhibitors or inducers of cytochromial enzymes and alcohol, should avoid the concomitant intake of BRONCHENOL COUGH ®.

Contraindications COUGH BRONCHENOL ® Dextromethorphan

The use of BRONCHENOL TOSSE ® is contraindicated in patients suffering from severe liver and kidney diseases, from respiratory diseases at high risk of respiratory failure and undergoing therapy with MAO inhibitor antidepressants.
Evidently the use of this drug is also contraindicated in patients hypersensitive to the active principle or to one of its excipients.

Undesirable Effects - Side Effects

The use of BRONCHENOL COUGH ® could cause, fortunately only rarely, drowsiness, nausea, vomiting, abdominal pain and dizziness.
Definitely rarer are adverse reactions of the neurological type associated with the disproportionate increase in Serotonin, known together with the name of Serotonin syndrome.
Even more rare are the adverse reactions associated with hypersensitivity to the active substance.


BRONCHENOL COUGH ® is a drug not subject to mandatory medical prescription.

The information on BRONCHENOL COUGH ® Dextromethorphan published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.

none:  video-exercises human-health pharmacology